Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Maxamine plus IL-2 improves survival in late-stage malignant melanoma

May 4, 2000

Neurocrine Biosciences obtains orphan drug status for glioblastoma therapy

May 2, 2000

Neurocrine Biosciences reports positive results from phase I/II malignant glioma trial

April 27, 2000

Campath MAA accepted for review by European authorities

April 26, 2000

Novelos Therapeutics initiates first U.S. trial of BAM-002

April 25, 2000

Coley initiates phase I/II trials of CpG-7909 for cancer

April 24, 2000

Preclinical results for Avax's AC Vaccine technology in breast cancer presented at AACR

April 14, 2000

SuperGen and AVI BioPharma establish marketing agreement for Avicine

April 11, 2000

Zadaxin plus chemotherapy shows promise in malignant melanoma

April 11, 2000

M-Vax shown to induce T-cell-mediated immune reactions in metastatic melanoma study

April 11, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...